Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Nelli Bejanyan, Brian J. Bolwell, Aleksandr Lazaryan, Lisa Rybicki, Shawnda Tench, Hien Duong, Steven Andresen, Ronald Sobecks, Robert Dean, Brad Pohlman, Matt Kalaycio, Edward A. Copelan Biology of Blood and Marrow Transplantation Volume 18, Issue 6, Pages 874-880 (June 2012) DOI: 10.1016/j.bbmt.2011.10.032 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Survival by readmission within 30 days of discharge. Biology of Blood and Marrow Transplantation 2012 18, 874-880DOI: (10.1016/j.bbmt.2011.10.032) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions